Status:
UNKNOWN
BEOVU in the Treatment of Dystrophy-related Macular Neovascular Degeneration
Lead Sponsor:
Benha University
Conditions:
Dystrophy, Retinal
Eligibility:
All Genders
18-50 years
Phase:
PHASE4
Brief Summary
Dystrophy-Related macular neovascularization degeneration occur is a vision threatening condition.The investigators evaluate the efficacy of BEOVU intravitreal treatment.
Detailed Description
Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination was done. Procedure included intravitreal injection of Brolucizumab (BEOVU®, Genen-tech, South Francisco, CA)
Eligibility Criteria
Inclusion
- Dystrophy-Related macular neovascularization degeneration
Exclusion
- age related macular degeneration , other causes of macular neovascularization degeneration
Key Trial Info
Start Date :
October 25 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04690062
Start Date
October 25 2020
End Date
December 30 2022
Last Update
December 30 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
INMC
Abu Dhabi, United Arab Emirates, 46266